Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 6/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16364071 | 0.83 | KDM4E (0.40) | NQO2PKN1PKN2KDM4ENR4A2 | |
| SCHEMBL15809074 | 0.81 | PARP1 (0.40) | NQO2GAATSHRPKN1PKN2 | |
| SCHEMBL15808713 | 0.81 | PRMT5 (0.42) | NQO2GAATSHRPKN1PKN2 | |
| SCHEMBL7471336 | 0.81 | PARP1 (0.39) | NQO2GAATSHRPKN1PKN2 | |
| SCHEMBL15808795 | 0.80 | PTGES (0.44) | — | |
| SCHEMBL15808720 | 0.80 | NQO2 (0.40) | NQO2GAATSHRPKN1PKN2 | |
| SCHEMBL15918408 | 0.79 | MAPT (0.39) | NQO2GAATSHRPKN1PKN2 | |
| SCHEMBL15808944 | 0.79 | MEN1 (0.41) | GAAMAPTPRMT5WDR77ALDH1A1 | |
| SCHEMBL15808833 | 0.79 | PARP1 (0.51) | RIPK1 | |
| SCHEMBL15808785 | 0.78 | MAPT (0.46) | NQO2GAATSHRMAPTPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732066-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINY AKU CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9216968-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINYAKU CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2746265-B1 | HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR | NIPPON SHINYAKU CO LTD (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2746265-A1 | HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG | Nippon Shinyaku Co., Ltd. (JP) | 2014-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | NQO2 1034/4885ABL1 3357/4885GAA 2700/4885 |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | NQO2 1034/4885ABL1 3357/4885GAA 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.